Skip to main content
  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

  • Home
  • About this Journal
    • General Statistics
    • Editorial Board
    • Editors
    • Information for Advertisers
    • Author Reprints
    • Commercial Reprints
    • Customer Service and Ordering Information
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • AHA Guidelines and Statements
    • Acknowledgment of Reviewers
    • Clinical Implications
    • Clinical-Pathological Conferences
    • Controversies in Hypertension
    • Editors' Picks
    • Guidelines Debate
    • Meeting Abstracts
    • Recent Advances in Hypertension
    • SPRINT Trial: the Conversation Continues
  • Resources
    • Instructions to Reviewers
    • Instructions for Authors
    • →Article Types
    • → Submission Guidelines
      • Research Guidelines
        • Minimum Information About Microarray Data Experiments (MIAME)
      • Abstract
      • Acknowledgments
      • Clinical Implications (Only by invitation)
      • Conflict(s) of Interest/Disclosure(s) Statement
      • Figure Legends
      • Figures
      • Novelty and Significance: 1) What Is New, 2) What Is Relevant?
      • References
      • Sources of Funding
      • Tables
      • Text
      • Title Page
      • Online/Data Supplement
    • →Tips for Easier Manuscript Submission
    • → General Instructions for Revised Manuscripts
      • Change of Authorship Form
    • → Costs to Authors
    • → Open Access, Repositories, & Author Rights Q&A
    • Permissions to Reprint Figures and Tables
    • Journal Policies
    • Scientific Councils
    • AHA Journals RSS Feeds
    • International Users
    • AHA Newsroom
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Genomic and Precision Medicine
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association
  • Facebook
  • Twitter

  • My alerts
  • Sign In
  • Join

  • Advanced search

Header Publisher Menu

  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

Hypertension

  • My alerts
  • Sign In
  • Join

  • Facebook
  • Twitter
  • Home
  • About this Journal
    • General Statistics
    • Editorial Board
    • Editors
    • Information for Advertisers
    • Author Reprints
    • Commercial Reprints
    • Customer Service and Ordering Information
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • AHA Guidelines and Statements
    • Acknowledgment of Reviewers
    • Clinical Implications
    • Clinical-Pathological Conferences
    • Controversies in Hypertension
    • Editors' Picks
    • Guidelines Debate
    • Meeting Abstracts
    • Recent Advances in Hypertension
    • SPRINT Trial: the Conversation Continues
  • Resources
    • Instructions to Reviewers
    • Instructions for Authors
    • →Article Types
    • → Submission Guidelines
    • →Tips for Easier Manuscript Submission
    • → General Instructions for Revised Manuscripts
    • → Costs to Authors
    • → Open Access, Repositories, & Author Rights Q&A
    • Permissions to Reprint Figures and Tables
    • Journal Policies
    • Scientific Councils
    • AHA Journals RSS Feeds
    • International Users
    • AHA Newsroom
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Genomic and Precision Medicine
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association
Original Articles

Induction of Heme Oxygenase 1 Attenuates Placental Ischemia–Induced Hypertension

Eric M. George, Kathy Cockrell, Marietta Aranay, Eva Csongradi, David E. Stec, Joey P. Granger
Download PDF
https://doi.org/10.1161/HYPERTENSIONAHA.111.169755
Hypertension. 2011;57:941-948
Originally published April 20, 2011
Eric M. George
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kathy Cockrell
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marietta Aranay
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eva Csongradi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David E. Stec
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joey P. Granger
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Info & Metrics
  • eLetters

Jump to

  • Article
    • Abstract
    • Methods
    • Results
    • Discussion
    • Sources of Funding
    • Disclosures
    • Footnotes
    • References
  • Figures & Tables
  • Info & Metrics
  • eLetters
Loading

Abstract

Recent in vitro studies have reported that heme oxygenase 1 (HO-1) downregulates the angiostatic protein soluble fms-like tyrosine kinase 1 from placental villous explants and that the HO-1 metabolites CO and bilirubin negatively regulate endothelin 1 and reactive oxygen species. Although soluble fms-like tyrosine kinase 1, endothelin 1, and reactive oxygen species have been implicated in the pathophysiology of hypertension during preeclampsia and in response to placental ischemia in pregnant rats, it is unknown whether chronic induction of HO-1 alters the hypertensive response to placental ischemia. The present study examined the hypothesis that HO-1 induction in a rat model of placental ischemia would beneficially affect blood pressure, angiogenic balance, superoxide, and endothelin 1 production in the ischemic placenta. To achieve this goal we examined the effects of cobalt protoporphyrin, an HO-1 inducer, in the reduced uterine perfusion pressure (RUPP) placental ischemia model and in normal pregnant rats. In response to RUPP treatment, mean arterial pressure increases 29 mm Hg (136±7 versus 106±5 mm Hg), which is significantly attenuated by cobalt protoporphyrin (118±5 mm Hg). Although RUPP treatment causes placental soluble fms-like tyrosine kinase 1/vascular endothelial growth factor ratios to alter significantly to an angiostatic balance (1.00±0.10 versus 1.27±0.20), treatment with cobalt protoporphyrin causes a significant shift in the ratio to an angiogenic balance (0.68±0.10). Placental superoxide increased in RUPP (952.5±278.8 versus 243.9±70.5 relative light units/min per milligram) but was significantly attenuated by HO-1 induction (482.7±117.4 relative light units/min per milligram). Also, the preproendothelin message was significantly increased in RUPP, which was prevented by cobalt protoporphyrin. These data indicate that HO-1, or its metabolites, is a potential therapeutic for the treatment of preeclampsia.

  • placental ischemia
  • soluble VEGF R1
  • preeclampsia
  • reduced uterine perfusion pressure
  • ET-1

Preeclampsia, a gestation-dependent hypertensive disorder, presents with proteinuria and vascular dysfunction after the twentieth week of pregnancy.1,2 It is relatively common, contributing to ≤15% of preterm births, and is a leading cause of maternal and fetal morbidity worldwide, additionally increasing the risk of later cardiovascular disease to the offspring.3,–,5 The exact cause of the disease is unknown, although it is thought to be a result of reduced placental perfusion, possibly through failure of fetally derived trophoblasts to adequately invade and remodel the maternal spiral arteries.6

As a consequence of inadequate placental perfusion, the placenta becomes increasingly hypoxic, as is indicated by the induction of hypoxia-responsive genes.7,8 The ischemic/hypoxic placenta has been shown in experimental animal models to be the source of many of the underlying physiological factors in the etiology of the disease, including generation of placental reactive oxygen species and imbalance of angiogenic and angiostatic factors, specifically vascular endothelial growth factor (VEGF) and soluble fms-like tyrosine kinase 1 (sFlt-1).9,10 These studies into animal models of placental ischemia have provided an important experimental system for the investigation of the pathophysiology of the disorder.

Recently, there has been substantial interest in the use of heme oxygenase 1 (HO-1) as a therapeutic agent in multiple forms of cardiovascular disease and hypertension (for thorough reviews, see References 11 and 12). HO-1 functions in the heme salvage pathway, removing the pro-oxidant free heme by converting it to bilirubin, a known antioxidant molecule, and CO, a potent vasodilator.13,–,15 HO-1 induction has been shown to be beneficial in models of renovascular hypertension, pulmonary hypertension, angiotensin II–dependent hypertension, and the spontaneously hypertensive rat model.11,16,–,18 It has been reported that induction of HO-1 in the placenta protects isolated villi from tumor necrosis factor-α induced cellular damage and promotes vascular relaxation.19 Further studies indicated that, in vitro, HO-1 induction and CO alone were capable of downregulating the angiostatic protein sFlt-1 production from placental villous explants and that CO negatively regulates endothelin 1 (ET-1) at the message level in endothelial cells.20,21 In addition, it has been reported that heterozygous knockout of HO-1 in mice results in inhibited placental development, elevated plasma sFlt-1, and increased maternal diastolic pressure.22

Although acute induction of HO-1 has been reported to negatively regulate many of the factors that are involved in the pathophysiology of hypertension in response to placental ischemia, it is not known whether chronic HO-1 induction alters the hypertensive response to placental ischemia during pregnancy. Therefore, the present study was undertaken to examine the hypothesis that HO-1 induction in a rat model of placental hypoxia/ischemia would have beneficial effects on blood pressure, angiogenic balance, and superoxide production in the ischemic placenta.

Methods

Animals

Timed pregnant Sprague-Dawley rats (Harlan, Inc, Indianapolis, IN) were received on day 10 or 11 of gestation. All of the protocols were approved by the University of Mississippi Medical Center Institutional Animal Care and Use Committee and followed the National Institutes of Health Guidelines for the Care and Use of Laboratory Animals. Rats were maintained on an 12:12 hour light:dark cycle, at 23°C constant temperature, and were provided food and water ad libitium.

Reduced Uterine Perfusion Pressure Procedure and Cobalt Protoporphyrin Treatment

On gestational day 14, reduced uterine perfusion pressure (RUPP)–treated animals were subjected to aortic and bilateral ovarian artery constriction as described previously.23 Briefly, animals were anesthetized by controlled 3% isoflurane (Webster), and a midline abdominal incision was made. After externalization of both uterine horns, 1 single 0.203-mm silver surgical clip was placed on the lower abdominal aorta above the iliac bifurcation. One 0.100-mm silver surgical clip was placed on both the left and right ovarian arteries, which supply the uterus to prevent compensatory flow. Rats absorbing all of the pups as a result of the procedure were excluded from the study. For HO-1 induction, Cobalt (III) protoporphyrin IX chloride (CoPP; Frontier Scientific, Logan, UT) was injected IP at a dose of 5 mg/kg on day 14 of gestation, at doses described previously.24,25

Measurement of Mean Arterial Pressure

On gestational day 18, rats were anesthetized as above and implanted with indwelling carotid catheters consisting of V-3 tubing (SCI). Catheters were tunneled subcutaneously and exteriorized at the back of the neck. The following day, rats were placed in individual restraining cages and acclimatized. Mean arterial pressure was measured consciously for 1 hour via Cobe III pressure transducers (CDX Sema). Each experimental group had 10 to 13 rats.

Tissue Harvest

Rats were anesthetized as above. After ventral midline incision, the uterus was externalized, and blood was collected by needle tapping of the abdominal aorta. The number of viable and reabsorbed pups was recorded in the uterus, and individual pups and placentas were weighed and recorded. Samples of the largest and smallest placentas from each horn, the thoracic aorta, and the liver were saved and flash frozen in liquid nitrogen before storage at −80°C for later analysis.

Measurement of VEGF and sFlt-1

Measurements of VEGF and sFlt-1 were made by sandwich ELISA (R&D Systems) in duplicate with internal standardization via supplied control protein. For placental measurements, the largest frozen placenta from an individual uterine horn was ground in a mortar and pestle while submerged in liquid nitrogen. Resulting particles were resuspended and homogenized in radioimmunoassay buffer with a multiprotease inhibitor mixture, PMSF, and sodium orthovanadate (Santa Cruz Biotechnology). Lysates were spun at 12 000g at 4°C for 20 minutes to remove cellular debris. Total protein concentration was measured by the bicinchoninic acid method (Pierce Biotechnology). VEGF and sFlt-1 were then measured and normalized to total protein concentration. Plasma obtained from the above harvests was assayed for VEGF concentration with the same assay kit. Each group had >6 rats. All of the samples were run in duplicate, with VEGF intra-assay and interassay variability of 6% and 7%, respectively, and sFlt-1 intra-assay and interassay variability of 5% and 7%, respectively.

Determination of Placental Superoxide

Placental extracts were prepared and protein concentration determined as above. Lysates were incubated with lucigenin at 5-μmol/L final concentration. Samples were allowed to dark equilibrate for 3 minutes before measurement. Luminescence was recorded continuously for 15 minutes by luminometer (Berthold, Oak Ridge, TN). Values from lucigenin-only blanks were subtracted from final numbers. Levels are expressed as relative light units per minute per milligram of total protein in the lysate, with n=5 to 7 in each group.

Western Blotting and HO Activity Assays

Determination of total HO activity (n=5 in each group) and tissue levels was performed as described previously.26 Briefly, for HO activity, tissue lysates were prepared and measured as above. Reactions were performed in 1.2 mL consisting of 2 mmol/L of glucose-6-phosphate, 0.2 U of glucose-6-phosphatedehydrogenase, 0.8 mmol/L of nicotinamide-adenine dinucleotide phosphate, 20.0 μmol/L of hemin, and 0.5 mg of protein from lysates. Incubations were allowed to proceed for 1 hour at 37°C. Resulting bilirubin was chloroform extracted, and concentration was determined by change in optical density at 464 to 530 nm, using an extinction coefficient of 40 mmol/L per centimeter. Activity was expressed as picomoles of bilirubin formed per hour per milligram of protein. Six samples were analyzed in each group.

For Western blots, 50 μg of protein were subjected to SDS-PAGE on 7.5% SDS-polyacrylamide gels (Bio-Rad). Membranes were blocked with Odyssey blocking buffer (LI-COR, Lincoln, NE) for 2 hours at room temperature. Primary incubation was undertaken overnight at 4°C with a rabbit anti HO-1 polyclonal antibody (StressGen, Vancouver, British Columbia, Canada) at 1:2000 and a mouse anti–β-actin antibody (Gentest) at 1:5000. Secondary antibody incubation was done with Alexa Fluor 680 goat antirabbit (Molecular Probes) and IRDye 800 goat antimouse IgG (Rockland) for 1 hour at room temperature. Fluorescence was detected on an Odyssey infrared imager (LI-COR) for simultaneous detection of both species. Blot analysis was performed with the supplied Odyssey software, and HO-1 was normalized to β-actin, with 3 in each group.

Detection of Preproendothelin By Quantitative RT-PCR

Preproendothelin mRNA levels were determined by quantitative RT-PCR. Segments of the aorta above the kidneys were harvested from rats and quick frozen immediately in liquid nitrogen. For RNA isolation, the samples were ground in liquid nitrogen, and total RNA was isolated with the RNeasy mini kit (Qiagen) per the manufacturer's instructions. cDNA was produced from 750 ng of total RNA by Superscript II in concert with oligo dT primers (Invitrogen). Measurements were made from 5 rats in each experimental group. Custom primers (Invitrogen) were used for both ET-1 and β-actin measurements. ET-1 primers used were forward (5′-CTAGGTCTAAGCGATCCTTG-3′) and reverse (5′-TTCTTGTCTGCTTGGC-3′). β-Actin primers used were forward (5-GCTCGTCGTCGACAACGGCTCCGGC-3′) and reverse (5′-CAAACATGATCTGGGTCATCTTCTCGCGG-3′). Real-time amplification was carried out with SYBR-Green Supermix (Bio-Rad) with a Bio-Rad iCycler undergoing 40 rounds of amplification. Relative fold change was determined by the 2Δ-ΔCt method, with 6 rats in all of the groups.

Statistical Analysis

All figures display mean data±SE. Data underwent Shapiro-Wilk tests for normal distribution, and comparisons between groups were performed by unpaired Student t test with a significance threshold value of P<0.05. All of the statistical comparisons and graphs were generated with OriginPro 8 (Microcal).

Results

CoPP Induces HO-1 Production in the Liver and Placenta of RUPP-Treated Rats

To induce HO-1 production, CoPP was administered at 5 mg/kg IP on day 14 of gestation. As indicated by Western blotting in Figure 1A and 1B, on day 19 of gestation, production of HO-1 in the placentas of control animals was unaffected by CoPP. RUPP animals actually demonstrated a significant (P<0.05) increase in HO-1 production of ≈60% compared with control animals. Most dramatically, however, RUPP animals treated with CoPP showed a ≈2.4-fold increase in HO-1 production versus normal pregnant controls. These findings were confirmed by analysis of total HO activity in the placenta of the 4 experimental groups. As shown in Figure 1C, despite increased expression of HO-1, total HO activity in the placenta of RUPP-treated rats is relatively unaffected by ischemia. In contrast, levels of HO activity in the placenta (Figure 1C) and liver (Figure 1D) of both control and RUPP rats were increased in response to CoPP treatment compared with normal pregnant rats, although, in the case of placental HO activity in RUPP rats, this failed to meet significance.

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

CoPP induces HO-1 production in RUPP rats. Placental HO-1 was measured by Western blot (A), and quantitation was performed by comparison with β-actin levels (B). HO-1 was increased in the placentas of both RUPP and RUPP-treated animals. HO activity was assayed in placental and liver lysates (C and D). CoPP induced increased HO activity in the liver of control and RUPP animals, while significantly increasing activity in the placenta of control animals. Error bars demonstrate SE.

HO-1 Induction Attenuates RUPP-Induced Hypertension in Pregnant Rats

We next wished to determine whether HO-1 induction was able to attenuate RUPP-induced hypertension. As demonstrated in Figure 2A, when the RUPP procedure is performed on day 14 of gestation, by gestational day 19, mean arterial pressure (MAP) is increased ≈29 mm Hg over controls (136±7 versus 106±5 mm Hg; P<0.05). CoPP administration to control animals had no statistical effect on MAP (104±8 mm Hg). Administration of CoPP to RUPP-treated animals, however, significantly attenuated the increase in MAP, decreasing pressure levels by 18 mm Hg versus RUPP-treated animals (118±5 versus 136±7 mm Hg; P<0.05). Together, these data indicate that HO-1 induction has a significant ability to attenuate the increase in MAP induced by the RUPP model of placental ischemia/hypoxia. It should be noted, however, that the induction of HO-1 expression had no effect on either pup or placental weight in control animals; it was also unable to significantly attenuate the RUPP-induced decreases in both pup weight and placental weight, as can be seen in Figure 2B and 2C. There were also no differences noted in the number of pups born to RUPP mothers in response to HO-1 induction (data not shown).

Figure 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

HO-1 induction attenuates RUPP-induced hypertension but has no significant effect on pup size. A, RUPP treatment led to a significant 29-mm Hg increase in MAP, which was significantly attenuated by HO-1 induction. B and C, HO-1 induction had no significant effect on either pup or placental mass. Error bars demonstrate SE.

HO-1 Induction Normalizes Placental Angiogenic Balance in RUPP Animals and Increases Circulating Free VEGF

To investigate the effect of HO-1 induction on RUPP-induced changes in VEGF expression, both plasma and placental extracts were examined by ELISA assay. Both VEGF and sFlt-1 are increased in response to RUPP treatment (23±5 versus 30±6 pg/mg for VEGF and 596±128 versus 997±245 pg/mg for sFlt-1). Although HO-1 induction had no effect on placental VEGF in normal pregnant rats (21±3 pg/mg), in RUPP rats VEGF levels were decreased to control levels (22±7 pg/mg). In contrast, sFlt-1 was decreased in both control (379±109 pg/mg) and RUPP (425±99 pg/mg) rats when HO-1 was induced by CoPP.

As shown in Figure 3A, in response to RUPP treatment, the ratio of placental sFlt-1/VEGF increases ≈25% versus controls (1.00±0.10 versus 1.27±0.20; P<0.05), indicating a shift in the balance of these 2 factors to a more angiostatic phenotype. In control rats, the ratio is decreased in rats treated with CoPP (0.68±0.10; P<0.05), indicating a significantly more angiogenic placental balance. Strikingly, in RUPP rats treated with CoPP, the ratio of sFlt-1/VEGF is decreased significantly from RUPP controls (0.79±0.10; P<0.05), indicating a net proangiogenic placental balance versus both normal pregnant and RUPP control rats.

Figure 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 3.

HO-1 induction normalized placental angiogenic balance in RUPP animals and promotes circulating VEGF. A, Placental levels of sFlt-1 and VEGF were determined by ELISA and molar ratio determined. In RUPP animals, sFlt-1/VEGF was increased, indicating an angiostatic phenotype. In response to HO-1 induction, the sFlt-1/VEGF ratio decreased significantly, indicating a net angiogenic balance. B, Circulating levels of VEGF were decreased significantly in response to RUPP treatment but were fully restored by induction of HO-1 by CoPP. Error bars demonstrate SE.

Circulating plasma levels of VEGF were also examined. As can be seen in Figure 3B, RUPP treatment decreased circulating free VEGF levels versus normal pregnant controls (363.1± 108.5 and 527.0±85.6 pg/mL, respectively; P<0.05). In response to CoPP induction of HO-1, circulating levels of free VEGF were unaffected in control rats. RUPP-treated rats, however, demonstrated normalization of circulating free VEGF levels in response to HO-1 induction.

HO Induction Reduces Production of Placental Superoxide in RUPP Rats

To investigate the effect of HO-1 induction on RUPP-induced superoxide production, placental samples from each control group were homogenized and subjected to lucigenin assays as described previously to measure superoxide levels in the tissue. As seen in Figure 4A, baseline levels of superoxide are increased in placental lysates as a result of RUPP treatment (952.5±278.8 versus 243.9±70.5 relative light units [RLU]/min per milligram; P<0.05). Although, with the induction of HO-1, there is a net increase in placental superoxide in control animals (617.4±225.3 RLU/min per milligram; P<0.05), in HO-1–induced animals, there is a net decrease in superoxide when compared with untreated RUPP animals (482.7±117.4 RLU/min per milligram; P<0.05). When activity of NADPH oxidase is examined in the same tissues by NADPH-dependent lucigenin luminescence, as shown in Figure 4B, NADPH oxidase activity is significantly elevated in RUPP placental samples versus normal pregnant rats (6600.8±2862.9 versus 2021.3±674.5 RLU/min per milligram; P<0.05). Placental NADPH activity is significantly increased in response to CoPP treatment (5525.6±2134.7 RLU/min per milligram; P<0.05), but again, in RUPP rats treated with CoPP, there is a decrease in NADPH activity versus untreated RUPP controls 3652.6±1288.9 RLU/min per milligram; P<0.05).

Figure 4.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 4.

HO-1 induction decreases oxidative stress in the ischemic placenta. RUPP treatment induced significant increases in baseline placental superoxide (A) and NADPH oxidase activity (B) in the placenta. Although administration of CoPP raised the baseline superoxide and NADPH oxidase activity in control animals, it also attenuated both in the RUPP group. Error bars demonstrate SE.

HO-1 Induction Reduces Placental Ischemia–Induced Increases in Vascular Preproendothelin

We next investigated the role of HO-1 induction in mediating vascular ET-1. To that end, we monitored preproendothelin message levels in the thoracic aorta of all experimental groups. As shown in Figure 5, in response to RUPP treatment, preproendothelin mRNA increased significantly in the aorta by ≈375% (1.06- versus 3.99-fold of control; P<0.05). With administration of CoPP, however, RUPP treatment only induced an ≈160% increase in vascular preproendothelin (1.8- versus 2.9-fold of control; P=0.31), half the increase in control rats, and failed to meet statistical significance. HO-1 induction then attenuated placental ischemia–induced preproendothelin at the message level.

Figure 5.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 5.

HO-1 induction attenuates placental ischemia–induced increases in vascular preproendothelin message production. Aorta from RUPP rats had a significantly increased expression of preproendothelin as assayed by quantitative RT-PCR. RUPP rats also demonstrated an increase in preproendothelin message, but the increase was markedly less and failed to meet statistical significance. Error bars represent SE.

Discussion

Currently the treatment options for preeclampsia are extremely limited, namely, induction of labor and delivery of the fetus and placenta. The present study raises interesting prospects for a therapeutic intervention for preeclampsia. Here we have once again demonstrated the importance of placental hypoxia and ischemia to the pathophysiology of preeclampsia. Furthermore, we have demonstrated that administration of CoPP, which has been shown to induce HO-1 expression at least partially through posttranscriptional manipulation of transcriptional repressor Bach1 and stabilization of transcription factor Nrf2,27,28 is able to induce expression and activity of HO-1 both systemically (eg, the liver) and specifically in the placenta of the pregnant rat. Although expression of the protein is clearly increased in RUPP rats treated with CoPP, the increase in activity is only mildly increased. This seeming incongruity is explained by the fact that HO-1 activity is inversely related to Po2, meaning that relatively minor changes in placental HO-1 activity are necessary to impact the corresponding observed changes in superoxide and angiogenic factors.29 This is also in agreement with early reports indicating that the increase in HO activity is not linearly related to protein expression induced by CoPP.30

Strikingly, we demonstrate that induction of HO-1 by CoPP in the RUPP model of preeclampsia is capable of significantly attenuating (Δ=18 mm Hg) the associated hypertension characteristic in this model while having no significant effect on non-RUPP–treated animals. Although there was no demonstrable increase in either pup or placenta weight with induction of HO-1, the possibility remains that HO-1 induction might prove beneficial to pup development in other, nonmechanically restricted models of the disorder.

In addition, we demonstrate that HO-1 induction has effects on multiple pathways associated with the increase in blood pressure in response to RUPP. It is now well documented that the imbalance of VEGF and sFlt-1 expression are important factors in the pathophysiology of preeclampsia, with the angiostatic sFlt-1 protein being in excess in both the placenta and systemic circulation.31,–,35 VEGF is a well-known factor in the survival and function of endothelial cells systemically, whereas sFlt-1, a soluble splice variant of the full-length VEGF receptor 1 membrane–bound receptor, is a powerful VEGF antagonist.36 Recent evidence has suggested that the ischemic placenta is a possible source of sFlt-1.36,–,40 Previous in vitro studies have demonstrated that HO-1 is capable of suppressing sFlt-1 release from isolated placental villous explants and that HO-1 inhibition promoted sFlt-1 release. This effect was further shown to be specifically mediated by its biologically active byproduct, CO.20 Here, we have demonstrated that HO-1 induction in an in vivo model is able to induce an angiogenic balance in the RUPP placenta, suggesting one possible mechanism for the attenuation of hypertension in this context. Although technical constraints made accurate measurement of circulating sFlt-1 impossible in the present study, we do demonstrate that levels of circulating free VEGF are increased in RUPP animals treated with CoPP, suggesting the possibility that vascular endothelial function, a recognized factor in the symptomatic development of preeclampsia, might be improved in response to HO-1 induction through an increase in circulating bioavailable VEGF.

A second pathway affected by HO-1 induction in the present study is the presence of superoxide in the ischemic placenta. We reiterate earlier findings that reactive oxygen is increased in the ischemic placenta and demonstrate that HO-1 induction is able to reduce the basal level of placental superoxide.9 One of the proposed mechanisms by which HO-1 is believed to be cytoprotective and beneficial in hypertension is through the antioxidant properties of bilirubin. Indeed, bilirubin efficiently prevents plasma lipid peroxidation, and it has been shown to convey cardioprotection during reperfusion.13,41 Here we have demonstrated that, whereas CoPP in normal pregnant rats mildly increases both placental superoxide and NADPH oxidase activity, it significantly decreases both superoxide and NADPH oxidase activity in RUPP-treated animals, suggesting the possibility that HO-1–derived bilirubin is functioning as an antioxidant buffer for excessive superoxide production in the RUPP model placenta. Whether the basal increases in superoxide seen here are an adverse effect of the CoPP treatment or HO-1 induction is not clear. Regardless, the net reduction of superoxide seen with HO-1 induction over RUPP control rats clearly demonstrates its overall beneficial effect. This provides a further possible mechanism by which HO-1 might function therapeutically in the treatment of preeclampsia.

We examined the production of vascular preproendothelin in response to HO-1 induction in the RUPP rat. Tissue production of preproendothelin mRNA has been shown to be elevated in the placentas of preeclamptic women.42,43 In addition, some studies have demonstrated elevated ET-1 in the maternal circulation during preeclampsia, although this effect was not seen universally.44,45 Animal studies looking at the role of tumor necrosis factor-α and sFlt-1, both believed to be derived from the ischemic placenta, have demonstrated induction of preproendothelin-1 in response to increased circulating maternal levels of the 2 factors.46,47 In our model of placental ischemia, we have demonstrated an important role for ET-1 in the etiology of placental ischemia–induced hypertension through its interaction with the endothelin A receptor.48

Here we have demonstrated that HO-1 induction markedly attenuates the induction of vascular preproendothelin in response to placental ischemia, reducing the induction by approximately half. The precise mechanism by which this occurs is not clear, but as has been demonstrated, CO negatively regulates the preproendothelin message in endothelial cells. Further work is necessary to determine whether CO is responsible for this effect in the in vivo model.

Finally, CoPP treatment in our study did not totally normalize blood pressure in the RUPP rats. The reason for this is not clear but could be because of the dose of CoPP used. Alternatively, it is likely that HO-1 induction does not affect all of the physiological pathways that are responsible for the increase in blood pressure in response to placental ischemia. The dose that we chose was based on previous studies that indicated it produces maximum blood pressure reduction. Thus, we speculate that the lack of normalization of blood pressure in the RUPP rats is attributed to an inability of HO-1 to affect all of the physiological pathways that are responsible for the increase in blood pressure in response to placental ischemia. We have reported previously that the blood pressure response to RUPP involves several pathways, including sFlt-1, reactive oxygen species, endothelin, and increases in tumor necrosis factor-α and angiotensin type 1 receptor autoantibodies. In this study we show that HO-1 induction attenuated the sFlt-1, reactive species, and endothelin responses to RUPP. Whether HO-1 induction attenuates the increase in tumor necrosis factor-α and angiotensin type 1 receptor autoantibodies is unknown.

Perspectives

Recent insights into the pathophysiology of preeclampsia have yielded insights into new potential therapeutic targets. Here we have demonstrated that HO-1 is capable of ameliorating the hypertension associated with placental ischemia/hypoxia. We further suggest 2 potential pathways through which HO-1 acts in this model, namely, return to normal angiogenic balance in the placenta and reduction in placental levels of oxidative stress. The ability to affect multiple pathological pathways makes HO-1 an intriguing potential approach for the treatment of preeclampsia. Further study into the mechanism of the attenuation of hypertension of HO-1 in this model, in addition to the role of its individual metabolites, CO and bilirubin, should provide an exciting new front in the treatment of preeclampsia.

Sources of Funding

This work was supported by National Institutes of Health grants HL51971, HL088421, and HL088421-S1.

Disclosures

None.

Footnotes

  • This paper was sent to Friedrich C. Luft, associate editor, for review by expert referees, editorial decision, and final disposition.

  • Received January 10, 2011.
  • Revision received January 28, 2011.
  • Accepted February 17, 2011.
  • © 2011 American Heart Association, Inc.

References

  1. 1.↵
    1. Roberts JM,
    2. Cooper DW
    . Pathogenesis and genetics of pre-eclampsia. Lancet.2001;357:53–56.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Granger JP,
    2. Alexander BT,
    3. Llinas MT,
    4. Bennett WA,
    5. Khalil RA
    . Pathophysiology of preeclampsia: linking placental ischemia/hypoxia with microvascular dysfunction. Microcirculation.2002;9:147–160.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Meis PJ,
    2. Goldenberg RL,
    3. Mercer BM,
    4. Iams JD,
    5. Moawad AH,
    6. Miodovnik M,
    7. Menard MK,
    8. Caritis SN,
    9. Thurnau GR,
    10. Bottoms SF,
    11. Das A,
    12. Roberts JM,
    13. McNellis D
    . The preterm prediction study: risk factors for indicated preterm births–Maternal-Fetal Medicine Units Network of the National Institute of Child Health and Human Development. Am J Obstet Gynecol.1998;178:562–567.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Zandi-Nejad K,
    2. Luyckx VA,
    3. Brenner BM
    . Adult hypertension and kidney disease: the role of fetal programming. Hypertension.2006;47:502–508.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    1. Sibai B,
    2. Dekker G,
    3. Kupferminc M
    . Pre-eclampsia. Lancet.2005;365:785–799.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Lim KH,
    2. Zhou Y,
    3. Janatpour M,
    4. McMaster M,
    5. Bass K,
    6. Chun SH,
    7. Fisher SJ
    . Human cytotrophoblast differentiation/invasion is abnormal in pre-eclampsia. Am J Pathol.1997;151:1809–1818.
    OpenUrlPubMed
  7. 7.↵
    1. Rajakumar A,
    2. Doty K,
    3. Daftary A,
    4. Harger G,
    5. Conrad KP
    . Impaired oxygen-dependent reduction of HIF-1α and -2α proteins in pre-eclamptic placentae. Placenta.2003;24:199–208.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Rajakumar A,
    2. Whitelock KA,
    3. Weissfeld LA,
    4. Daftary AR,
    5. Markovic N,
    6. Conrad KP
    . Selective overexpression of the hypoxia-inducible transcription factor, HIF-2α, in placentas from women with preeclampsia. Biol Reprod.2001;64:499–506.
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    1. Sedeek M,
    2. Gilbert JS,
    3. LaMarca BB,
    4. Sholook M,
    5. Chandler DL,
    6. Wang Y,
    7. Granger JP
    . Role of reactive oxygen species in hypertension produced by reduced uterine perfusion in pregnant rats. Am J Hypertens.2008;21:1152–1156.
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    1. Gilbert JS,
    2. Babcock SA,
    3. Granger JP
    . Hypertension produced by reduced uterine perfusion in pregnant rats is associated with increased soluble fms-like tyrosine kinase-1 expression. Hypertension.2007;50:1142–1147.
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    1. Cao J,
    2. Inoue K,
    3. Li X,
    4. Drummond G,
    5. Abraham NG
    . Physiological significance of heme oxygenase in hypertension. Int J Biochem Cell Biol.2009;41:1025–1033.
    OpenUrlCrossRefPubMed
  12. 12.↵
    1. Idriss NK,
    2. Blann AD,
    3. Lip GY
    . Hemoxygenase-1 in cardiovascular disease. J Am Coll Cardiol.2008;52:971–978.
    OpenUrlCrossRefPubMed
  13. 13.↵
    1. Neuzil J,
    2. Stocker R
    . Free and albumin-bound bilirubin are efficient co-antioxidants for α-tocopherol, inhibiting plasma and low density lipoprotein lipid peroxidation. J Biol Chem.1994;269:16712–16719.
    OpenUrlAbstract/FREE Full Text
  14. 14.↵
    1. Neuzil J,
    2. Stocker R
    . Bilirubin attenuates radical-mediated damage to serum albumin. FEBS Lett.1993;331:281–284.
    OpenUrlCrossRefPubMed
  15. 15.↵
    1. Wu L,
    2. Wang R
    . Carbon monoxide: endogenous production, physiological functions, and pharmacological applications. Pharmacol Rev.2005;57:585–630.
    OpenUrlAbstract/FREE Full Text
  16. 16.↵
    1. Botros FT,
    2. Schwartzman ML,
    3. Stier CT Jr.,
    4. Goodman AI,
    5. Abraham NG
    . Increase in heme oxygenase-1 levels ameliorates renovascular hypertension. Kidney Int.2005;68:2745–2755.
    OpenUrlCrossRefPubMed
  17. 17.↵
    1. Sabaawy HE,
    2. Zhang F,
    3. Nguyen X,
    4. ElHosseiny A,
    5. Nasjletti A,
    6. Schwartzman M,
    7. Dennery P,
    8. Kappas A,
    9. Abraham NG
    . Human heme oxygenase-1 gene transfer lowers blood pressure and promotes growth in spontaneously hypertensive rats. Hypertension.2001;38:210–215.
    OpenUrlAbstract/FREE Full Text
  18. 18.↵
    1. Yang L,
    2. Quan S,
    3. Nasjletti A,
    4. Laniado-Schwartzman M,
    5. Abraham NG
    . Heme oxygenase-1 gene expression modulates angiotensin II-induced increase in blood pressure. Hypertension.2004;43:1221–1226.
    OpenUrlAbstract/FREE Full Text
  19. 19.↵
    1. Ahmed A,
    2. Rahman M,
    3. Zhang X,
    4. Acevedo CH,
    5. Nijjar S,
    6. Rushton I,
    7. Bussolati B,
    8. St John J
    . Induction of placental heme oxygenase-1 is protective against TNFα-induced cytotoxicity and promotes vessel relaxation. Mol Med.2000;6:391–409.
    OpenUrlPubMed
  20. 20.↵
    1. Cudmore M,
    2. Ahmad S,
    3. Al-Ani B,
    4. Fujisawa T,
    5. Coxall H,
    6. Chudasama K,
    7. Devey LR,
    8. Wigmore SJ,
    9. Abbas A,
    10. Hewett PW,
    11. Ahmed A
    . Negative regulation of soluble Flt-1 and soluble endoglin release by heme oxygenase-1. Circulation.2007;115:1789–1797.
    OpenUrlAbstract/FREE Full Text
  21. 21.↵
    1. Morita T,
    2. Kourembanas S
    . Endothelial cell expression of vasoconstrictors and growth factors is regulated by smooth muscle cell-derived carbon monoxide. J Clin Invest.1995;96:2676–2682.
    OpenUrlCrossRefPubMed
  22. 22.↵
    1. Zhao H,
    2. Wong RJ,
    3. Kalish FS,
    4. Nayak NR,
    5. Stevenson DK
    . Effect of heme oxygenase-1 deficiency on placental development. Placenta.2009;30:861–868.
    OpenUrlCrossRefPubMed
  23. 23.↵
    1. Alexander BT,
    2. Kassab SE,
    3. Miller MT,
    4. Abram SR,
    5. Reckelhoff JF,
    6. Bennett WA,
    7. Granger JP
    . Reduced uterine perfusion pressure during pregnancy in the rat is associated with increases in arterial pressure and changes in renal nitric oxide. Hypertension.2001;37:1191–1195.
    OpenUrlAbstract/FREE Full Text
  24. 24.↵
    1. Jiang K,
    2. Cheng L,
    3. Wang J,
    4. Li J,
    5. Nie J
    . Heme oxygenase-1 expression in rats with acute lung rejection and implication. J Huazhong Univ Sci Technolog Med Sci.2009;29:84–87.
    OpenUrlCrossRefPubMed
  25. 25.↵
    1. Rosa AO,
    2. Egea J,
    3. Lorrio S,
    4. Rojo AI,
    5. Cuadrado A,
    6. Lopez MG
    . Nrf2-mediated haeme oxygenase-1 up-regulation induced by cobalt protoporphyrin has antinociceptive effects against inflammatory pain in the formalin test in mice. Pain.2008;137:332–339.
    OpenUrlCrossRefPubMed
  26. 26.↵
    1. Vera T,
    2. Kelsen S,
    3. Yanes LL,
    4. Reckelhoff JF,
    5. Stec DE
    . HO-1 induction lowers blood pressure and superoxide production in the renal medulla of angiotensin II hypertensive mice. Am J Physiol Regul Integr Comp Physiol.2007;292:R1472–R1478.
    OpenUrlAbstract/FREE Full Text
  27. 27.↵
    1. Shan Y,
    2. Pepe J,
    3. Lu TH,
    4. Elbirt KK,
    5. Lambrecht RW,
    6. Bonkovsky HL
    . Induction of the heme oxygenase-1 gene by metalloporphyrins. Arch Biochem Biophys.2000;380:219–227.
    OpenUrlCrossRefPubMed
  28. 28.↵
    1. Shan Y,
    2. Lambrecht RW,
    3. Donohue SE,
    4. Bonkovsky HL
    . Role of Bach1 and Nrf2 in up-regulation of the heme oxygenase-1 gene by cobalt protoporphyrin. FASEB J.2006;20:2651–2653.
    OpenUrlAbstract/FREE Full Text
  29. 29.↵
    1. Appleton SD,
    2. Marks GS,
    3. Nakatsu K,
    4. Brien JF,
    5. Smith GN,
    6. Graham CH
    . Heme oxygenase activity in placenta: direct dependence on oxygen availability. Am J Physiol Heart Circ Physiol.2002;282:H2055–H2059.
    OpenUrlAbstract/FREE Full Text
  30. 30.↵
    1. Sardana MK,
    2. Kappas A
    . Dual control mechanism for heme oxygenase: tin(IV)-protoporphyrin potently inhibits enzyme activity while markedly increasing content of enzyme protein in liver. Proc Natl Acad Sci U S A.1987;84:2464–2468.
    OpenUrlAbstract/FREE Full Text
  31. 31.↵
    1. Gilbert JS,
    2. Ryan MJ,
    3. LaMarca BB,
    4. Sedeek M,
    5. Murphy SR,
    6. Granger JP
    . Pathophysiology of hypertension during preeclampsia: linking placental ischemia with endothelial dysfunction. Am J Physiol Heart Circ Physiol.2008;294:H541–H550.
    OpenUrlAbstract/FREE Full Text
  32. 32.↵
    1. Li Z,
    2. Zhang Y,
    3. Ying Ma J,
    4. Kapoun AM,
    5. Shao Q,
    6. Kerr I,
    7. Lam A,
    8. O'Young G,
    9. Sannajust F,
    10. Stathis P,
    11. Schreiner G,
    12. Karumanchi SA,
    13. Protter AA,
    14. Pollitt NS
    . Recombinant vascular endothelial growth factor 121 attenuates hypertension and improves kidney damage in a rat model of preeclampsia. Hypertension.2007;50:686–692.
    OpenUrlAbstract/FREE Full Text
  33. 33.↵
    1. Suzuki H,
    2. Ohkuchi A,
    3. Matsubara S,
    4. Takei Y,
    5. Murakami M,
    6. Shibuya M,
    7. Suzuki M,
    8. Sato Y
    . Effect of recombinant placental growth factor 2 on hypertension induced by full-length mouse soluble fms-like tyrosine kinase 1 adenoviral vector in pregnant mice. Hypertension.2009;54:1129–1135.
    OpenUrlAbstract/FREE Full Text
  34. 34.↵
    1. Gilbert JS,
    2. Verzwyvelt J,
    3. Colson D,
    4. Arany M,
    5. Karumanchi SA,
    6. Granger JP
    . Recombinant vascular endothelial growth factor 121 infusion lowers blood pressure and improves renal function in rats with placentalischemia-induced hypertension. Hypertension.2010;55:380–385.
    OpenUrlAbstract/FREE Full Text
  35. 35.↵
    1. Karumanchi SA,
    2. Epstein FH
    . Placental ischemia and soluble fms-like tyrosine kinase 1: cause or consequence of preeclampsia? Kidney Int.2007;71:959–961.
    OpenUrlCrossRefPubMed
  36. 36.↵
    1. Maynard SE,
    2. Min JY,
    3. Merchan J,
    4. Lim KH,
    5. Li J,
    6. Mondal S,
    7. Libermann TA,
    8. Morgan JP,
    9. Sellke FW,
    10. Stillman IE,
    11. Epstein FH,
    12. Sukhatme VP,
    13. Karumanchi SA
    . Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest.2003;111:649–658.
    OpenUrlCrossRefPubMed
  37. 37.↵
    1. Nagamatsu T,
    2. Fujii T,
    3. Kusumi M,
    4. Zou L,
    5. Yamashita T,
    6. Osuga Y,
    7. Momoeda M,
    8. Kozuma S,
    9. Taketani Y
    . Cytotrophoblasts up-regulate soluble fms-like tyrosine kinase-1 expression under reduced oxygen: an implication for the placental vascular development and the pathophysiology of preeclampsia. Endocrinology.2004;145:4838–4845.
    OpenUrlCrossRefPubMed
  38. 38.↵
    1. Ahmad S,
    2. Ahmed A
    . Elevated placental soluble vascular endothelial growth factor receptor-1 inhibits angiogenesis in preeclampsia. Circ Res.2004;95:884–891.
    OpenUrlAbstract/FREE Full Text
  39. 39.↵
    1. Nevo O,
    2. Many A,
    3. Xu J,
    4. Kingdom J,
    5. Piccoli E,
    6. Zamudio S,
    7. Post M,
    8. Bocking A,
    9. Todros T,
    10. Caniggia I
    . Placental expression of soluble fms-like tyrosine kinase 1 is increased in singletons and twin pregnancies with intrauterine growth restriction. J Clin Endocrinol Metab.2008;93:285–292.
    OpenUrlCrossRefPubMed
  40. 40.↵
    1. Nevo O,
    2. Soleymanlou N,
    3. Wu Y,
    4. Xu J,
    5. Kingdom J,
    6. Many A,
    7. Zamudio S,
    8. Caniggia I
    . Increased expression of sFlt-1 in in vivo and in vitro models of human placental hypoxia is mediated by HIF-1. Am J Physiol Regul Integr Comp Physiol.2006;291:R1085–R1093.
    OpenUrlAbstract/FREE Full Text
  41. 41.↵
    1. Clark JE,
    2. Foresti R,
    3. Sarathchandra P,
    4. Kaur H,
    5. Green CJ,
    6. Motterlini R
    . Heme oxygenase-1-derived bilirubin ameliorates postischemic myocardial dysfunction. Am J Physiol Heart Circ Physiol.2000;278:H643–H651.
    OpenUrlAbstract/FREE Full Text
  42. 42.↵
    1. Napolitano M,
    2. Miceli F,
    3. Calce A,
    4. Vacca A,
    5. Gulino A,
    6. Apa R,
    7. Lanzone A
    . Expression and relationship between endothelin-1 messenger ribonucleic acid (mRNA) and inducible/endothelial nitric oxide synthase mRNA isoforms from normal and preeclamptic placentas. J Clin Endocrinol Metab.2000;85:2318–2323.
    OpenUrlCrossRefPubMed
  43. 43.↵
    1. Faxen M,
    2. Nasiell J,
    3. Lunell NO,
    4. Blanck A
    . Differences in mRNA expression of endothelin-1, c-fos and c-jun in placentas from normal pregnancies and pregnancies complicated with preeclampsia and/or intrauterine growth retardation. Gynecol Obstet Invest.1997;44:93–96.
    OpenUrlPubMed
  44. 44.↵
    1. Taylor RN,
    2. Varma M,
    3. Teng NN,
    4. Roberts JM
    . Women with preeclampsia have higher plasma endothelin levels than women with normal pregnancies. J Clin Endocrinol Metab.1990;71:1675–1677.
    OpenUrlCrossRefPubMed
  45. 45.↵
    1. Benigni A,
    2. Orisio S,
    3. Gaspari F,
    4. Frusca T,
    5. Amuso G,
    6. Remuzzi G
    . Evidence against a pathogenetic role for endothelin in pre-eclampsia. Br J Obstet Gynaecol.1992;99:798–802.
    OpenUrlPubMed
  46. 46.↵
    1. LaMarca BB,
    2. Cockrell K,
    3. Sullivan E,
    4. Bennett W,
    5. Granger JP
    . Role of endothelin in mediating tumor necrosis factor-induced hypertension in pregnant rats. Hypertension.2005;46:82–86.
    OpenUrlAbstract/FREE Full Text
  47. 47.↵
    1. Murphy SR,
    2. LaMarca BB,
    3. Cockrell K,
    4. Granger JP
    . Role of endothelin in mediating soluble fms-like tyrosine kinase 1-induced hypertension in pregnant rats. Hypertension.2010;55:394–398.
    OpenUrlAbstract/FREE Full Text
  48. 48.↵
    1. Alexander BT,
    2. Rinewalt AN,
    3. Cockrell KL,
    4. Massey MB,
    5. Bennett WA,
    6. Granger JP
    . Endothelin type a receptor blockade attenuates the hypertension in response to chronic reductions in uterine perfusion pressure. Hypertension.2001;37:485–489.
    OpenUrlAbstract/FREE Full Text
View Abstract
Back to top
Previous ArticleNext Article

This Issue

Hypertension
May 2011, Volume 57, Issue 5
  • Table of Contents
Previous ArticleNext Article

Jump to

  • Article
    • Abstract
    • Methods
    • Results
    • Discussion
    • Sources of Funding
    • Disclosures
    • Footnotes
    • References
  • Figures & Tables
  • Info & Metrics
  • eLetters

Article Tools

  • Print
  • Citation Tools
    Induction of Heme Oxygenase 1 Attenuates Placental Ischemia–Induced Hypertension
    Eric M. George, Kathy Cockrell, Marietta Aranay, Eva Csongradi, David E. Stec and Joey P. Granger
    Hypertension. 2011;57:941-948, originally published April 20, 2011
    https://doi.org/10.1161/HYPERTENSIONAHA.111.169755

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
  •  Download Powerpoint
  • Article Alerts
    Log in to Email Alerts with your email address.
  • Save to my folders

Share this Article

  • Email

    Thank you for your interest in spreading the word on Hypertension.

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    Induction of Heme Oxygenase 1 Attenuates Placental Ischemia–Induced Hypertension
    (Your Name) has sent you a message from Hypertension
    (Your Name) thought you would like to see the Hypertension web site.
  • Share on Social Media
    Induction of Heme Oxygenase 1 Attenuates Placental Ischemia–Induced Hypertension
    Eric M. George, Kathy Cockrell, Marietta Aranay, Eva Csongradi, David E. Stec and Joey P. Granger
    Hypertension. 2011;57:941-948, originally published April 20, 2011
    https://doi.org/10.1161/HYPERTENSIONAHA.111.169755
    del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Related Articles

Cited By...

Subjects

  • Cardiology
    • Etiology
      • Hypertension
        • Hypertension
  • Basic, Translational, and Clinical Research
    • Animal Models of Human Disease

Hypertension

  • About Hypertension
  • Instructions for Authors
  • AHA CME
  • Guidelines and Statements
  • Permissions
  • Journal Policies
  • Email Alerts
  • Open Access Information
  • AHA Journals RSS
  • AHA Newsroom

Editorial Office Address:
7272 Greenville Ave.
Dallas, TX 75231
email: hypertension@heart.org

Information for:
  • Advertisers
  • Subscribers
  • Subscriber Help
  • Institutions / Librarians
  • Institutional Subscriptions FAQ
  • International Users
American Heart Association Learn and Live
National Center
7272 Greenville Ave.
Dallas, TX 75231

Customer Service

  • 1-800-AHA-USA-1
  • 1-800-242-8721
  • Local Info
  • Contact Us

About Us

Our mission is to build healthier lives, free of cardiovascular diseases and stroke. That single purpose drives all we do. The need for our work is beyond question. Find Out More about the American Heart Association

  • Careers
  • SHOP
  • Latest Heart and Stroke News
  • AHA/ASA Media Newsroom

Our Sites

  • American Heart Association
  • American Stroke Association
  • For Professionals
  • More Sites

Take Action

  • Advocate
  • Donate
  • Planned Giving
  • Volunteer

Online Communities

  • AFib Support
  • Garden Community
  • Patient Support Network
  • Professional Online Network

Follow Us:

  • Follow Circulation on Twitter
  • Visit Circulation on Facebook
  • Follow Circulation on Google Plus
  • Follow Circulation on Instagram
  • Follow Circulation on Pinterest
  • Follow Circulation on YouTube
  • Rss Feeds
  • Privacy Policy
  • Copyright
  • Ethics Policy
  • Conflict of Interest Policy
  • Linking Policy
  • Diversity
  • Careers

©2018 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. The American Heart Association is a qualified 501(c)(3) tax-exempt organization.
*Red Dress™ DHHS, Go Red™ AHA; National Wear Red Day ® is a registered trademark.

  • PUTTING PATIENTS FIRST National Health Council Standards of Excellence Certification Program
  • BBB Accredited Charity
  • Comodo Secured